XNCR - Xencor, Inc.
| Previous Close | 31.06 |
| Open | 31.25 |
| Bid | 12.00 x 800 |
| Ask | 31.90 x 900 |
| Day's Range | 30.00 - 31.85 |
| 52 Week Range | 27.57 - 48.38 |
| Volume | 148,973 |
| Avg. Volume | 225,075 |
| Market Cap | 1.765B |
| Beta (3Y Monthly) | 0.82 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.31 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 42.90 |
- Business Wire•17 days ago
Xencor and Astellas Enter Collaboration for Novel Bispecific Antibody Program
Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced it has entered into a research and license agreement in which Astellas Pharma Inc. will access Xencor’s bispecific technology to advance a novel bispecific antibody program in oncology. Xencor and Astellas will collaborate to generate bispecific antibodies directed toward a selected anti-tumor target for the potential treatment of patients with cancer, and Astellas will have an exclusive worldwide license to develop and commercialize novel drug candidates.
- Business Wire•17 days ago
Xencor to Participate in Upcoming Investor Conferences
Xencor, Inc. , a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and alle
- Simply Wall St.•17 days ago
Why I Like Xencor, Inc. (NASDAQ:XNCR)
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Xencor, Inc. (NASDAQ:XNCR) is a company with exceptional fundamental characteristics. Upon building up an investment...
- Markit•23 days ago
See what the IHS Markit Score report has to say about Xencor Inc.
Xencor Inc NASDAQ NMS:XNCRView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and increasing Bearish sentimentShort interest | NeutralShort interest is moderate for XNCR with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on March 25. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding XNCR are favorable, with net inflows of $2.62 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Business Wire•last month
Xencor Announces Closing of Research Collaboration and License Agreement with Genentech
Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced the closing of its research collaboration and license agreement with Genentech, a member of the Roche Group, following the expiration of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976. Xencor and Genentech entered the agreement to develop and commercialize novel IL-15 cytokine therapeutics, including XmAb®24306, an IL-15/IL-15Rα cytokine complex engineered with Xencor’s bispecific Fc domain and Xtend™ Fc technology.
- GlobeNewswire•last month
New Research Coverage Highlights Clovis Oncology, Welltower, The Ultimate Software Group, Nielsen Holdings Plc, Xencor, and 21Vianet Group — Consolidated Revenues, Company Growth, and Expectations for 2019
NEW YORK, March 06, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Simply Wall St.•2 months ago
Is Xencor, Inc.’s (NASDAQ:XNCR) CEO Paid Enough Relative To Peers?
In 2005 Bassil Dahiyat was appointed CEO of Xencor, Inc. (NASDAQ:XNCR). First, this article will compare CEO compensation with compensation at similar sized companies. Then we'll look at a snapRead More...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of XNCR earnings conference call or presentation 25-Feb-19 9:30pm GMT
Q4 2018 Xencor Inc Earnings Call
- GuruFocus.com•2 months ago
Xencor Inc (XNCR) Files 10-K for the Fiscal Year Ended on December 31, 2018
Xencor Inc (NASDAQ:XNCR) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018.
- Zacks•2 months ago
Nielsen (NLSN) to Report Q4 Earnings: What's in the Offing?
Partnerships and agreements are likely to drive Nielsen's (NLSN) fourth-quarter 2018 revenues. However, weakness in the Buy segment and increasing competition may impact its profits.
Motley Fool•2 months agoXencor Inc (XNCR) Q4 2018 Earnings Conference Call Transcript
XNCR earnings call for the period ending December 31, 2018.
- PR Newswire•2 months ago
Xencor Reports Fourth Quarter and Full Year 2018 Financial Results
- Initial Data from Phase 1 Study of XmAb®14045 Presented at ASH 2018; Multiple Complete Remissions Achieved in Advanced AML Patient Population; Study on Partial Clinical Hold Pending Resolution with FDA ...
- ACCESSWIRE•2 months ago
Xencor, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 25, 2019 / Xencor, Inc. (NASDAQ: XNCR ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 25, 2019 at 4:30 PM Eastern ...
- Zacks•2 months ago
What's in Store for Booking Holdings' (BKNG) Q4 Earnings?
Booking Holdings' (BKNG) Q4 earnings are likely to reflect growth in international markets.
- Zacks•2 months ago
Strong Friday Close Secures a 9th Week in the Green
Strong Friday Close Secures a 9th Week in the Green
- PR Newswire•2 months ago
Xencor Announces Partial Clinical Hold on Phase 1 Study of XmAb14045
MONROVIA, Calif., Feb. 20, 2019 /PRNewswire/ -- Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on its Phase 1 study of XmAb14045, a CD123 x CD3 bispecific antibody molecule being evaluated in patients with relapsed or refractory acute myeloid leukemia and other CD123-expressing hematologic malignancies. No new patients will be allowed to enroll in the study until the partial clinical hold is lifted by the FDA.
- PR Newswire•2 months ago
Xencor to Host Fourth Quarter and Full Year 2018 Financial Results Webcast and Conference Call on February 25, 2019
MONROVIA, Calif. , Feb. 19, 2019 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, ...
- PR Newswire•2 months ago
Xencor to Present at Upcoming Investor Conferences
MONROVIA, Calif. , Feb. 7, 2019 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, ...
- PR Newswire•2 months ago
Xencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with Genentech
MONROVIA, Calif., Feb. 5, 2019 /PRNewswire/ -- Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic disease, and cancer, today announced it has entered into a research and license agreement with Genentech, a member of the Roche Group, to develop and commercialize novel IL-15 cytokine therapeutics, including XmAb®24306. XmAb24306 is an IL-15/IL-15Rα cytokine complex engineered with Xencor's bispecific Fc domain and Xtend™ Fc technology and is Xencor's most advanced preclinical cytokine program.
- GlobeNewswire•3 months ago
Report: Developing Opportunities within ONEOK, Alaska Air Group, Comcast, Mack-Cali Realty, Vistra Energy, and Xencor — Future Expectations, Projections Moving into 2019
NEW YORK, Jan. 28, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Simply Wall St.•3 months ago
Have Insiders Been Selling Xencor, Inc. (NASDAQ:XNCR) Shares This Year?
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be remiss not to mention that insider sales have Read More...
